Male Hypogonadism – Global API Manufacturers, Marketed and Phase III Drugs Landscape 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Male
Hypogonadism-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2016”
report to their offering.

Male Hypogonadism-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2016, provides comprehensive insights about the marketed
drugs, drug sales, Phase III pipeline drugs and their API Manufacturers
across the globe.

A key objective of the Male Hypogonadism Report is to understand the
market and pipeline status of the drugs around the Male Hypogonadism to
explore the generic development opportunities, licensing opportunities
and to gain competitive advantage on designing pipeline strategies. The
Report provides the historical and forecasted sales of the drugs till

The Report gives insights into patents providing the patent protection
data and marketing exclusivity of all the drugs across the Male
Hypogonadism, while the leading brands, companies and chemicals are
considered thoroughly.

The Report also provides details on the Global API Manufacturers across
the globe covering Drug Master Filings of US, Europe and API
Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Male Hypogonadism

7. Phase III Drugs for Male Hypogonadism

8. Discontinued Drugs for Male Hypogonadism

9. Appendix

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals